Search results
Author(s):
David Antoniucci
,
Roxana Mehran
,
Giuseppe DeLuca
,
et al
Added:
3 years ago
The use of coronary artery stents was first described in 1986, and percutaneous coronary intervention (PCI) involving stenting is now routine practice. However the problem of restenosis, caused by neointimal tissue growth, led to the development of drug-eluting stents (DES), which allow controlled release of antiproliferative drugs at the arterial wall.1 The use of DES has significantly improved…
View more
Author(s):
Didier Carrie
,
Marco Valgimigli
,
Gennaro Sardella
,
et al
Added:
3 years ago
Percutaneous coronary intervention (PCI) involving stenting is routine practice, and involves either bare metal stents (BMS) or drug-eluting stents (DES), which allow controlled release of antiproliferative drugs at the arterial waazll.1 However, the persistence of durable polymers in first-generation DES led to numerous problems including inflammation, delayed arterial healing, aneurysm…
View more
Author(s):
Didier Carrie
Added:
3 years ago
According to the International Diabetes Federation, 382 million people had diabetes in 2013, with diabetes mellitus (DM) accounting for around 90 % of all diabetes cases. By 2025 the number will rise to 592 million.1 The association between DM and cardiovascular disease is well established2 and percutaneous coronary intervention (PCI) is associated with worse clinical and angiographic outcomes…
View more
Author(s):
Robert A Byrne
,
Eric Eeckhout
,
Gennaro Sardella
,
et al
Added:
3 years ago
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are established strategies for revascularisation in patients with coronary artery disease. While CABG was the standard of care for patients with multivessel disease, the introduction of baremetal stents (BMSs) and, later, drug-eluting stents (DESs) has led to an increased use of PCI in these more challenging cases…
View more
Author(s):
Robert A Byrne
,
Shmuel Banai
,
Roisin Colleran
,
et al
Added:
3 years ago
Newer generation polymeric metallic drug-eluting stents (DES) have shown improved efficacy and safety compared with bare-metal stents and first-generation DES, improving patient outcomes after percutaneous coronary intervention (PCI) and facilitating the treatment of more complex coronary disease.1 However, clinical outcomes in certain lesion and patient subsets remain suboptimal. Procedural and…
View more
Author(s):
Katrina Mountfort
Added:
3 years ago
Proceedings of Two Satellite Symposia Held at EuroPCR in May 2015 in Paris
The use of second-generation polymeric metallic drug-eluting stents (DES) in percutaneous coronary intervention (PCI) is now routine practice and has demonstrated excellent safety and efficacy compared with first-generation DES. These stents have enhanced PCI procedures, enabling the treatment of more complex lesions and…
View more
Author(s):
Rafael Romaguera
Added:
2 years ago
In this short interview, Dr Rafael Romaguera (University of Barcelona, SP) discusses the findings from the SUGAR trial.This randomized head-to-head trial aimed to compare Cre8 EVO stents to a contemporary drug-eluting stent (DES) in patients with diabetes (DM) and coronary artery disease. The trial, first presented at TCT 2021, demonstrated that Cre8 EVO stents were non-inferior to Resolute Onyx…
View more
Eric Eeckhout
Research Area(s) / Expertise:
Job title: Associate Professor of Cardiology
Author
Foreword
Author(s):
Simon Kennon
Added:
3 years ago
Article
Marco Valgimigli
Research Area(s) / Expertise:
Job title: Deputy Chief of Cardiology
Author